Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunological studies of coagulation factor XIII.

E D Israels, F Paraskevas, L G Israels

    The Journal of Clinical Investigation
    |October 1, 1973
    PubMed
    Summary

    Human fibrin-stabilizing factor (Factor XIII) comprises two components: alpha and beta. Congenital Factor XIII deficiency lacks the functional alpha-component responsible for clot stabilization, retaining only the beta-component.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The haemoglobins of the foetus and newborn.

    Canadian journal of research. Section E, Medical sciences·2014
    Same author

    The role of the foetal haemoglobins in the aetiology of jaundice of the newborn.

    Canadian journal of research. Section E, Medical sciences·2014
    Same author

    The treatment of bleeding disorders.

    Canadian family physician Medecin de famille canadien·2010
    Same author

    Chemotherapy of hematological malignancies.

    Canadian family physician Medecin de famille canadien·2010
    Same author

    Novel vitamin K-dependent pathways regulating cell survival.

    Apoptosis : an international journal on programmed cell death·2001
    Same author

    The cell cycle.

    Stem cells (Dayton, Ohio)·2001

    Area of Science:

    • Hematology
    • Immunology
    • Biochemistry

    Background:

    • Human fibrin-stabilizing factor (Factor XIII) plays a crucial role in blood coagulation.
    • Previous studies suggested Factor XIII's complexity, but its immunological and functional components were not fully elucidated.

    Purpose of the Study:

    • To immunologically characterize the components of human Factor XIII.
    • To investigate the role of each component in clot stabilization and thrombin interaction.
    • To understand the immunological profile of Factor XIII in patients with congenital deficiency.

    Main Methods:

    • Preparation of specific anti-Factor XIII antiserum in rabbits.
    • Immunodiffusion assays to identify precipitin lines in plasma and platelet extracts.
    • Adsorption techniques to isolate antibodies specific to different Factor XIII components.
    • Clot stabilization assays to measure Factor XIII activity.
    • Thrombin treatment to assess its effect on Factor XIII components and activity.

    Main Results:

    • Normal plasma exhibited two precipitin lines (alpha and beta components) on immunodiffusion, with alpha from platelets and beta from serum.
    • Plasma and serum from patients with congenital Factor XIII deficiency only contained the beta-component.
    • Antisera against Factor XIII neutralized clot-stabilizing activity.
    • Thrombin treatment abolished the alpha-line but not the clot-stabilizing neutralization capacity, indicating the alpha-component's role.

    Conclusions:

    • Human Factor XIII consists of two immunologically distinct components: alpha and beta.
    • The alpha-component contains the clot-stabilizing activity and the thrombin-reactive site.
    • Congenital Factor XIII deficiency is characterized by the absence of the functional alpha-component, while the beta-component remains detectable.

    Related Experiment Videos